Potassium News and Research

RSS

Phase 3 results of TARGET 1 and TARGET 2 clinical trials released

Salix Pharmaceuticals, Ltd. today announced the successful outcome of two Phase 3, randomized, double-blind, placebo-controlled, multicenter trials, TARGET 1 and TARGET 2, designed to evaluate the efficacy and safety of rifaximin 550 mg TID in the treatment of patients with non-constipation irritable bowel syndrome (non-C IBS).

14 Sep 2009

Phase III STARTMRK clinical study on ISENTRESS in comparison to efavirenz

ISENTRESS , an integrase inhibitor from Merck & Co., Inc., was studied in comparison to efavirenz in maintaining viral load suppression to undetectable levels (less than 50 copies/mL) and at improving CD4 cell counts in previously untreated (treatment-naïve) HIV-1-infected patients through 96 weeks in a Phase III study called STARTMRK.

14 Sep 2009

NeuroMetrix completes private placement of common stock and warrants

NeuroMetrix, Inc., today announced that it has completed its private placement of common stock and warrants. Gross proceeds from the offering were approximately $18.7 million.

11 Sep 2009

A non-invasive test for cystic fibrosis is the goal of University Of Arizona researchers

Researchers from The University of Arizona Colleges of Pharmacy and Medicine are teaming up to try to invent a novel non-invasive lung test for cystic fibrosis sufferers.

10 Sep 2009

Caldolor launched ahead of schedule in U.S. by Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) announced today that it has successfully implemented the U.S. launch of Caldolor((R)), an intravenous formulation of ibuprofen, designed primarily for use in the hospital setting.

9 Sep 2009

FDA approves Salix' METOZOLV ODT for treating diabetic gastroparesis

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced the U.S. Food and Drug Administration (FDA) has granted marketing approval for METOZOLV™ ODT (metoclopramide HCl) 5mg and 10mg orally disintegrating tablets. METOZOLV ODT is indicated for the relief of symptoms in adults associated with acute and recurrent diabetic gastroparesis and for the treatment of short-term therapy (4-12 weeks) for adults with symptomatic documented gastroesophageal reflux disease (GERD) who fail to respond to conventional therapy1.

9 Sep 2009

NeuroMetrix to purchase $18.68 million of its common stock

NeuroMetrix, Inc., a healthcare company transforming patient care through neurotechnology, today announced that it has obtained commitments from institutional investors to purchase approximately $18.68 million of its common stock in a private placement.

9 Sep 2009

Heart health of kidney disease patients not affected by dialysis treatment

Dialysis treatments do not affect the heart health of kidney disease patients who have had a heart attack, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology (CJASN). Since cardiovascular disease is the most common cause of death in kidney disease patients, the findings are good news for individuals who need the treatments.

1 Sep 2009

Chlorella green food sourced from algae contains a wide range of essential nutrients

"While we can still take advantage of summer's fresh produce, ensuring a consistent supply of whole foods throughout the year can reap benefits for those focused on aging as healthfully as possible," says Michael E. Rosenbaum, M.D. "Chlorella, a super green food sourced from a fresh water algae, contains the widest range of essential nutrients available in any single food source, including potassium, all B vitamins, magnesium, zinc, iron and 18 vital amino acids." Though beneficial for all life stages, Sun Chlorella can especially help aging adults thanks to these health rewards.

1 Sep 2009

Pennsylvania Department of Health to commence distribution of new KI tablets next month

The Department of Health will provide free potassium iodide, or KI, tablets to people who live or work within a 10-mile radius of Pennsylvania's five nuclear power plants beginning next month.

29 Aug 2009

Free-living microalgae be used as broad-spectrum automated biosensor systems for continuous monitoring of drinking water

A method to detect contaminants in municipal water supplies has undergone further refinements by two Oak Ridge National Laboratory researchers whose findings are published on line in Water Environment Research.

29 Aug 2009

Comprehensive review on the pharmacology of sigma receptors published in Journal of Pharmacology Therapeutics

Anavex Life Sciences Corp. ("ANAVEX" or the "Company") reports the publication of a comprehensive review of the pharmacology of sigma receptors and their possible clinical application in the peer-reviewed Journal of Pharmacology Therapeutics.

28 Aug 2009

Cumberland Pharmaceuticals posts $9.8 million revenues for the three months ended June 30, 2009

Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on the hospital acute care and gastroenterology markets, today announced second quarter 2009 financial results.

27 Aug 2009

Consumer Reports covers issues pertaining to the efficacy and safety of prescription and non-prescription drugs

Consumer Reports and ConsumerReportsHealth.org cover issues pertaining to the efficacy and safety of prescription and non-prescription drugs (including natural medicines), mental health, diet and nutrition, food safety, and fitness.

26 Aug 2009

FDA accepts for filing Salix Pharmaceuticals' NDA for rifaximin tablets

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced the Food and Drug Administration (FDA) has accepted for filing and designated for Priority Review the Company’s New Drug Application (NDA) for rifaximin tablets 550 mg for the maintenance of remission of hepatic encephalopathy (HE). Additionally, the FDA has informed the Company of its plan to schedule an Advisory Committee meeting in late February 2010 to discuss the application.

25 Aug 2009

FDA issues marketing approval for APP Pharmaceuticals' Penicillin G potassium for Injection, USP

APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc. (NASDAQ: APCVZ), announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market penicillin G potassium for Injection, USP, in two dosage strengths. Penicillin G is therapeutically equivalent to the reference drug PfizerPen™ G, which is marketed by the innovator Pfizer, Inc.

25 Aug 2009

Retigabine's Phase IIa clinical trial preliminary results announced

Valeant Pharmaceuticals International today announced preliminary results from its Phase IIa proof-of-concept clinical trial of retigabine for the treatment of pain associated with postherpetic neuralgia (PHN), a painful and common complication of shingles.

24 Aug 2009

Study reveals high cholestrol as a cause of cardiac arrhythmias

Cholesterol can affect the flow of the electrical currents that generate the heart beat, according to a study from two UBC cardiovascular researchers funded by the Heart and Stroke Foundation of BC & Yukon. The research team has just published the important discovery about the causes of cardiac arrhythmias (abnormal heartbeats) in one of the world's leading scientific journals.

24 Aug 2009

Gene discovery unveils a new protein that protects against hearing loss

Discovery of a deafness-causing gene defect in mice has helped identify a new protein that protects sensory cells in the ear, according to a study by University of Iowa and Kansas State University researchers. The findings appear in the August 21 issue of the open-access journal PLoS Genetics.

24 Aug 2009

Discovery of mechanism that allows hepatitis C virus to remain in the body for decades

A study published in the Proceedings of the National Academy of Sciences (PNAS) shows that the virus blocks the actions of a specific ion channel in the cell membrane that would usually trigger apoptosis - the cell's self-destruct programme - and in doing so, has evolved another way of protecting itself from being eliminated from the body.

19 Aug 2009

Potassium News and Research

Phase 3 results of TARGET 1 and TARGET 2 clinical trials released

Phase III STARTMRK clinical study on ISENTRESS in comparison to efavirenz

NeuroMetrix completes private placement of common stock and warrants

A non-invasive test for cystic fibrosis is the goal of University Of Arizona researchers

Caldolor launched ahead of schedule in U.S. by Cumberland Pharmaceuticals

FDA approves Salix' METOZOLV ODT for treating diabetic gastroparesis

NeuroMetrix to purchase $18.68 million of its common stock

Heart health of kidney disease patients not affected by dialysis treatment

Chlorella green food sourced from algae contains a wide range of essential nutrients

Pennsylvania Department of Health to commence distribution of new KI tablets next month

Free-living microalgae be used as broad-spectrum automated biosensor systems for continuous monitoring of drinking water

Comprehensive review on the pharmacology of sigma receptors published in Journal of Pharmacology Therapeutics

Cumberland Pharmaceuticals posts $9.8 million revenues for the three months ended June 30, 2009

Consumer Reports covers issues pertaining to the efficacy and safety of prescription and non-prescription drugs

FDA accepts for filing Salix Pharmaceuticals' NDA for rifaximin tablets

FDA issues marketing approval for APP Pharmaceuticals' Penicillin G potassium for Injection, USP

Retigabine's Phase IIa clinical trial preliminary results announced

Study reveals high cholestrol as a cause of cardiac arrhythmias

Gene discovery unveils a new protein that protects against hearing loss

Discovery of mechanism that allows hepatitis C virus to remain in the body for decades

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News